Ceryvyn Therapeutics Ltd
OPT
Rank in Stocks
#31863
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Share Price
$0.00846342
Last synced: 2026-07-27
Market Cap
$11.27M
Change (1 day)
0.00%
Change (1 year)
-99.75%
Country
AU
Trade Ceryvyn Therapeutics Ltd (OPT)
Category
Healthcare
P/E ratio for Ceryvyn Therapeutics Ltd (OPT)
P/E ratio as of October 2026 TTM: -3.28
According to Ceryvyn Therapeutics Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.28. At the end of 2024 the company had a P/E ratio of -1.00.
P/E ratio history for Ceryvyn Therapeutics Ltd from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -3.28 | -27.30% |
| 2025 | -4.51 | 351.53% |
| 2024 | -1.00 | 23.24% |
| 2023 | -0.81 | -63.33% |
| 2022 | -2.21 | -60.63% |
| 2021 | -5.62 | -85.27% |
| 2020 | -38.14 | 442.47% |
| 2019 | -7.03 | -2.49% |
| 2018 | -7.21 | -67.93% |
| 2017 | -22.49 | 72.70% |
| 2016 | -13.02 | 150.42% |
| 2015 | -5.20 | 97.14% |
| 2014 | -2.64 | 1.34% |
| 2013 | -2.60 | -26.34% |
| 2012 | -3.53 | 34.58% |
| 2011 | -2.63 | -36.18% |
| 2010 | -4.11 | -5.89% |
| 2009 | -4.37 | -88.34% |
| 2008 | -37.49 | -688.73% |
| 2007 | 6.37 | -166.90% |
| 2006 | -9.52 | -388.15% |
| 2005 | 3.30 | -85.55% |
| 2004 | 22.87 | -176.80% |
| 2003 | -29.78 | 36.98% |
| 2002 | -21.74 | -84.97% |
| 2001 | -144.64 | -166.57% |
| 2000 | 217.29 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -977.82% |
US
|
|
| -28.36 | 764.90% |
US
|
|
| -24.57 | 649.26% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -1,025.03% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.